These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22792314)

  • 1. Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy.
    Alkhalaf A; Kleefstra N; Groenier KH; Bilo HJ; Gans RO; Heeringa P; Scheijen JL; Schalkwijk CG; Navis GJ; Bakker SJ
    PLoS One; 2012; 7(7):e40427. PubMed ID: 22792314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relations of advanced glycation endproducts and dicarbonyls with endothelial dysfunction and low-grade inflammation in individuals with end-stage renal disease in the transition to renal replacement therapy: A cross-sectional observational study.
    Martens RJH; Broers NJH; Canaud B; Christiaans MHL; Cornelis T; Gauly A; Hermans MMH; Konings CJAM; van der Sande FM; Scheijen JLJM; Stifft F; Wirtz JJJM; Kooman JP; Schalkwijk CG
    PLoS One; 2019; 14(8):e0221058. PubMed ID: 31408493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes.
    Stirban A; Negrean M; Stratmann B; Gawlowski T; Horstmann T; Götting C; Kleesiek K; Mueller-Roesel M; Koschinsky T; Uribarri J; Vlassara H; Tschoepe D
    Diabetes Care; 2006 Sep; 29(9):2064-71. PubMed ID: 16936154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study.
    Persson F; Rossing P; Hovind P; Stehouwer CD; Schalkwijk CG; Tarnow L; Parving HH
    Scand J Clin Lab Invest; 2008; 68(8):731-8. PubMed ID: 18609080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased levels of N(epsilon)-(carboxymethyl)lysine and N(epsilon)-(carboxyethyl)lysine in type 1 diabetic patients with impaired renal function: correlation with markers of endothelial dysfunction.
    Lieuw-A-Fa ML; van Hinsbergh VW; Teerlink T; Barto R; Twisk J; Stehouwer CD; Schalkwijk CG
    Nephrol Dial Transplant; 2004 Mar; 19(3):631-6. PubMed ID: 14767019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease.
    Vlassara H; Uribarri J; Cai W; Goodman S; Pyzik R; Post J; Grosjean F; Woodward M; Striker GE
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):934-42. PubMed ID: 22461535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of diabetic nephropathy from advanced glycation endproducts (AGEs) differs in plasma and urine, and is dependent on the method of preparation.
    Beisswenger PJ; Howell SK; Russell G; Miller ME; Rich SS; Mauer M
    Amino Acids; 2014 Feb; 46(2):311-9. PubMed ID: 24036985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy.
    Alkhalaf A; Klooster A; van Oeveren W; Achenbach U; Kleefstra N; Slingerland RJ; Mijnhout GS; Bilo HJ; Gans RO; Navis GJ; Bakker SJ
    Diabetes Care; 2010 Jul; 33(7):1598-601. PubMed ID: 20413516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dietary intake of advanced glycation endproducts is associated with higher levels of advanced glycation endproducts in plasma and urine: The CODAM study.
    Scheijen JLJM; Hanssen NMJ; van Greevenbroek MM; Van der Kallen CJ; Feskens EJM; Stehouwer CDA; Schalkwijk CG
    Clin Nutr; 2018 Jun; 37(3):919-925. PubMed ID: 29381139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose thiamine therapy counters dyslipidemia and advanced glycation of plasma protein in streptozotocin-induced diabetic rats.
    Karachalias N; Babaei-Jadidi R; Kupich C; Ahmed N; Thornalley PJ
    Ann N Y Acad Sci; 2005 Jun; 1043():777-83. PubMed ID: 16037305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct associations of HbA1c and the urinary excretion of pentosidine, an advanced glycosylation end-product, with markers of endothelial function in insulin-dependent diabetes mellitus.
    Smulders RA; Stehouwer CD; Schalkwijk CG; Donker AJ; van Hinsbergh VW; TeKoppele JM
    Thromb Haemost; 1998 Jul; 80(1):52-7. PubMed ID: 9684785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat.
    Balakumar P; Chakkarwar VA; Singh M
    Mol Cell Biochem; 2009 Jan; 320(1-2):149-62. PubMed ID: 18830571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N(epsilon)-(carboxymethyl)lysine levels in patients with type 2 diabetes: role of renal function.
    Wagner Z; Wittmann I; Mazák I; Schinzel R; Heidland A; Kientsch-Engel R; Nagy J
    Am J Kidney Dis; 2001 Oct; 38(4):785-91. PubMed ID: 11576882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between advanced glycation endproducts and matrix metalloproteinases and its inhibitor in individuals with type 1 diabetes.
    Peeters SA; Engelen L; Buijs J; Theilade S; Rossing P; Schalkwijk CG; Stehouwer CDA
    J Diabetes Complications; 2018 Mar; 32(3):325-329. PubMed ID: 29395841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial.
    Gibson GE; Luchsinger JA; Cirio R; Chen H; Franchino-Elder J; Hirsch JA; Bettendorff L; Chen Z; Flowers SA; Gerber LM; Grandville T; Schupf N; Xu H; Stern Y; Habeck C; Jordan B; Fonzetti P
    J Alzheimers Dis; 2020; 78(3):989-1010. PubMed ID: 33074237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary intake of advanced glycation end products did not affect endothelial function and inflammation in healthy adults in a randomized controlled trial.
    Semba RD; Gebauer SK; Baer DJ; Sun K; Turner R; Silber HA; Talegawkar S; Ferrucci L; Novotny JA
    J Nutr; 2014 Jul; 144(7):1037-42. PubMed ID: 24744309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble intercellular adhesion molecule, vascular cell adhesion molecule, and impaired microvascular reactivity are early markers of vasculopathy in type 2 diabetic individuals without microalbuminuria.
    Lim SC; Caballero AE; Smakowski P; LoGerfo FW; Horton ES; Veves A
    Diabetes Care; 1999 Nov; 22(11):1865-70. PubMed ID: 10546021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1.
    van Eupen MG; Schram MT; Colhoun HM; Hanssen NM; Niessen HW; Tarnow L; Parving HH; Rossing P; Stehouwer CD; Schalkwijk CG
    Diabetologia; 2013 Aug; 56(8):1845-55. PubMed ID: 23620061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine.
    Babaei-Jadidi R; Karachalias N; Ahmed N; Battah S; Thornalley PJ
    Diabetes; 2003 Aug; 52(8):2110-20. PubMed ID: 12882930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ellisras Longitudinal Study 2017: elevated serum levels of carboxymethyl-lysine, an advanced glycation end-product, are associated with higher odds of developing endothelial dysfunction in black South African patients with type 2 diabetes mellitus (ELS 29).
    Mogale MA; Mhlanga CM; Gololo SS; Adu A
    Cardiovasc J Afr; 2019 Jul/Aug 23; 30(4):193-197. PubMed ID: 31469381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.